Amr Radwan

623 total citations
50 papers, 388 citations indexed

About

Amr Radwan is a scholar working on Hepatology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amr Radwan has authored 50 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hepatology, 10 papers in Epidemiology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amr Radwan's work include Liver Disease and Transplantation (10 papers), Asthma and respiratory diseases (8 papers) and Liver Disease Diagnosis and Treatment (7 papers). Amr Radwan is often cited by papers focused on Liver Disease and Transplantation (10 papers), Asthma and respiratory diseases (8 papers) and Liver Disease Diagnosis and Treatment (7 papers). Amr Radwan collaborates with scholars based in Egypt, United Kingdom and United States. Amr Radwan's co-authors include Mahmoud M. Sakr, Andrew Menzies‐Gow, Robert Niven, Neil Barnes, David A. Spencer, Adel Mansur, Carol Stonham, Mike Thomas, Manuela Tvaronavičienė and Mark Hudson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Gut.

In The Last Decade

Amr Radwan

45 papers receiving 368 citations

Peers

Amr Radwan
Deniz Köksal Türkiye
Minyoung Her South Korea
Victor Olsavszky Germany
Naveenraj L. Solomon United States
Farrukh Iqbal Pakistan
Adam L. Booth United States
Richard Nolan Australia
Hsiu‐Chen Teng Taiwan
Kamel Senouci France
Bülent Yılmaz Türkiye
Deniz Köksal Türkiye
Amr Radwan
Citations per year, relative to Amr Radwan Amr Radwan (= 1×) peers Deniz Köksal

Countries citing papers authored by Amr Radwan

Since Specialization
Citations

This map shows the geographic impact of Amr Radwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amr Radwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amr Radwan more than expected).

Fields of papers citing papers by Amr Radwan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amr Radwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amr Radwan. The network helps show where Amr Radwan may publish in the future.

Co-authorship network of co-authors of Amr Radwan

This figure shows the co-authorship network connecting the top 25 collaborators of Amr Radwan. A scholar is included among the top collaborators of Amr Radwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amr Radwan. Amr Radwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peters, Anju T., Jayant M. Pinto, Eugenio De Corso, et al.. (2025). Dupilumab Effectiveness Through Two Years in Patients with CRSwNP Treated in Real-World Practice: Results from the Global AROMA Registry. Journal of Allergy and Clinical Immunology. 155(2). AB186–AB186.
2.
Abdel‐Bar, Hend Mohamed, et al.. (2025). Tailored Intranasal Albumin Caged Selegiline-α Synuclein siRNA Liposome with Improved Efficiency in Parkinson’s Model. Pharmaceutics. 17(2). 243–243. 3 indexed citations
3.
Chehade, Mirna, et al.. (2025). A Real-World Study of Cumulative Steroid Burden Among Patients With Eosinophilic Esophagitis in the United States. Clinical Gastroenterology and Hepatology. 23(9). 1665–1667.e3.
4.
Chehade, Mirna, et al.. (2024). Disease Burden and Spectrum of Symptoms That Impact Quality of Life in Pediatric Patients With Eosinophilic Esophagitis. SHILAP Revista de lepidopterología. 3(8). 1054–1068. 2 indexed citations
5.
Korn, Stephanie, Olaf Schmidt, Hartmut Timmermann, et al.. (2023). Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study. Respiration. 103(1). 10–21.
6.
Radwan, Amr, et al.. (2023). Research, development and innovation in business enterprises: experience from Egypt. SHILAP Revista de lepidopterología. 5(1). 41–58. 5 indexed citations
7.
Radwan, Amr, et al.. (2022). The big picture of climate change research in the Arab world: insights from bibliometric analysis. Journal of Entrepreneurship and Sustainability Issues. 10(2). 653–671. 3 indexed citations
8.
Radwan, Amr, et al.. (2022). Women in science, technology, engineering, and mathematics (STEM) 'Egyptian case study'. SHILAP Revista de lepidopterología. 4(4). 52–62. 6 indexed citations
9.
Musa, Sherief, Shereen Abdel Alem, Khaled Amer, et al.. (2021). Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study. Journal of Infection and Public Health. 14(10). 1466–1473. 8 indexed citations
10.
Radwan, Amr, Naglaa M. El-Lakkany, Samia William, et al.. (2019). A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. Parasites & Vectors. 12(1). 304–304. 28 indexed citations
11.
Jones, Stacie M., Brian P. Vickery, J. Andrew Bird, et al.. (2017). At-home Dosing Adherence During Characterized Oral Desensitization Immunotherapy (CODIT) for Peanut Allergy. Journal of Allergy and Clinical Immunology. 139(2). AB256–AB256. 1 indexed citations
12.
Berni, Ellen, et al.. (2015). Cost Effectiveness of Rifaximin-Á 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In United Kingdom. Value in Health. 18(7). A626–A626. 3 indexed citations
13.
Berni, Ellen, et al.. (2015). Evaluation of The Cost Effectiveness of Rifaximin-Á In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Belgium. Value in Health. 18(7). A628–A628. 3 indexed citations
14.
Berni, Ellen, et al.. (2015). Evaluation of The Cost Effectiveness of Rifaximin-á 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Sweden. Value in Health. 18(7). A626–A626. 6 indexed citations
15.
16.
Orr, James, et al.. (2014). PTU-127 Resource Use Associated With Hepatic Encephalopathy In Patients With Severe Liver Disease. Gut. 63(Suppl 1). A94.2–A95. 3 indexed citations
17.
Barnes, Neil, Andrew Menzies‐Gow, Adel Mansur, et al.. (2013). Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study. Journal of Asthma. 50(5). 529–536. 96 indexed citations
18.
Zayed, Naglaa, Wafaa Elakel, Wahid Doss, et al.. (2012). The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology. 37(3). 254–261. 15 indexed citations
19.
20.
Ray, Ahmed El, Rami Moucari, Tarik Asselah, et al.. (2010). 1058 INSULIN RESISTANCE: A MAJOR PREDICTOR OF SIGNIFICANT LIVER FIBROSIS IN EGYPTIAN PATIENTS WITH GENOTYPE 4 CHRONIC HEPATITIS C. Journal of Hepatology. 52. S409–S409. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deniz Köksal Breakdown of academic impact, for papers by Minyoung Her Breakdown of academic impact, for papers by Victor Olsavszky Breakdown of academic impact, for papers by Naveenraj L. Solomon Breakdown of academic impact, for papers by Farrukh Iqbal Breakdown of academic impact, for papers by Adam L. Booth Breakdown of academic impact, for papers by Richard Nolan Breakdown of academic impact, for papers by Hsiu‐Chen Teng Breakdown of academic impact, for papers by Kamel Senouci Breakdown of academic impact, for papers by Bülent Yılmaz
Rankless by CCL
2026